DOCSLIB.ORG

ACNP 57Th Annual Meeting: Panels, Mini-Panels and Study Groups

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ACNP 57Th Annual Meeting: Panels, Mini-Panels and Study Groups www.nature.com/npp ABSTRACTS COLLECTION ACNP 57th Annual Meeting: Panels, Mini-Panels and Study Groups Sponsorship Statement: Publication of this supplement is sponsored by the ACNP. Individual contributor disclosures may be found within the abstracts. Asterisks in the author lists indicate presenter of the abstract at the annual meeting. https://doi.org/10.1038/s41386-018-0265-8 Panel experiments were performed in 8-10-week-old male or female mice on a C57 background. 1. Dissecting the Contributions of Dopamine D1 and D2 Results: We observed dendritic atrophy in NAc D1-MSNs but Receptor-Expressing Neurons in Behaviors Dysregulated in not D2-MSNs in CSDS susceptible mice (P < 0.001). mRNAs of RhoA Neuropsychiatric Illness pathway molecules were significantly altered in D1-MSNs of CSDS susceptible mice (P < 0.05). Genetic overexpression of WT-RhoA in D1-MSNs induced dendritic atrophy and a susceptible outcome to 1.1 Dichotomous Structural Adaptations in Nucleus SSDS (P < 0.01), while DN-RhoA in D1-MSNs restored dendritic Accumbens Neuron Subtypes Underlie Stress Susceptibility complexity and caused a resilient outcome to CSDS (P < 0.05) compared to eYFP controls. RhoA (WT) in D1-MSNs caused reduced time grooming in splash test of female mice, reduced Mary Kay Lobo sucrose preference in male mice, and enhanced time immobile in forced swim test of both sexes (P < 0.05). Increased Egr3, the RhoA University of Maryland School of Medicine, Baltimore, Maryland, transcriptional regulator, in D2-MSNs promotes stress resiliency (P United States < 0.05) by preventing D2-MSN enhanced density of mushroom spines that occurs in stress susceptible mice (P < 0.01), without Background: Ventral striatum (nucleus accumbens-NAc) medium altering dendritic arbor. spiny neurons (MSNs) undergo structural plasticity after stress. Conclusions: D1-MSNs display dendritic atrophy and D2-MSNs However, there is little information into these adaptations, and the have enhanced dendritic spines in CSDS susceptible mice. underlying molecular mechanisms, in the two NAc MSN subtypes, Enhanced levels of the transcription factor Egr3 and its target those enriched in dopamine receptor 1 and 2 (D1-MSNs vs. D2- RhoA mediate D1-MSN dendritic atrophy and corresponding CSDS MSNs). Previously we showed that enhanced levels of the susceptible behavior. In contrast, enhanced Egr3 in D2-MSNs transcription factor, early growth response 3 (Egr3), caused blocks dendritic spine formation and causes stress resiliency. dendritic atrophy and depression-like behavior after 10-day Overall, we demonstrate dichotomous structural, molecular, and chronic social defeat stress (CSDS). We further showed that Egr3 behavioral outcomes to social defeat stress through NAc D1-MSNs transcriptionally regulates RhoA, a negative regulator of dendritic vs. D2-MSNs. complexity. However, it is unclear if RhoA or other structural Disclosure: Nothing to disclose. molecules regulate these morphological adaptations and whether these changes also occur in D2-MSNs. Methods: Using D1-Cre and A2A-Cre lines we examined dendritic complexity in NAc D1-MSNs vs. D2-MSNs of male mice 1.2 Cooperative Synaptic and Intrinsic Plasticity in Nucleus after CSDS. We used D1-Cre and A2A-Cre mice crossed to the Cre- Accumbens D1 Medium-Sized Spiny Neurons Promotes Stress- inducible RiboTag line to isolate and examine mRNAs of RhoA Induced Anhedonia and Behavioral Despair pathway molecules in MSN subtypes of stress susceptible mice and controls. We then infused Cre-inducible wildtype (WT)-RhoA, Hugo Tejeda dominate negative (DN)-RhoA, or eYFP adeno-associated virus (AAVs) into NAc of D1-Cre mice and subjected them to 1-day National Institute on Drug Abuse/National Institutes of Health, subthreshold (S)SDS or CSDS. To examine sex specific depression- Baltimore, Maryland, United States like effects of RhoA in D1-MSNs, unstressed male and female D1- Cre mice receiving RhoA AAVs into NAc underwent the splash test, sucrose preference, and forced swim test. Finally, to determine if Background: Stress is a powerful trigger of symptoms in Egr3, the upstream transcriptional regulator of RhoA, plays a role psychiatric disorders. Anhedonia and behavioral despair are in D2-MSNs in CSDS behavior and dendritic morphology we hallmark symptoms in a plethora of psychiatric disorders, infused Cre-inducible Egr3 AAV into NAc of A2A-Cre mice. Samples including depression. The nucleus accumbens (NAcc) is a brain sizes are 6-12 or 4-6 (pooled 4 mice; RiboTag experiments). region that has been widely implicated in mediating these Statistical analysis was performed with Two-way-ANOVAs. All symptoms. However, it is currently not clear how stress impacts © American College of Neuropsychopharmacology 2018 ACNP 57th Annual Meeting: Panels, Mini-Panels. S2 synaptic plasticity and intrinsic excitability in the NAcc, and how others sleep less. We recently showed that chronic social defeat they promote anhedonia and behavioral despair. stress (CSDS) in mice causes persistent alterations in sleep Methods: Utilizing a combination of ex-vivo electrophysiology, architecture, producing increases in time spent in paradoxical male and female transgenic mice, optogenetics, and viral- sleep (PS) as well as increases in the number of PS bouts that mediated gene transfer, we determined the impact of footshock persisted after cessation of the stressor. Previous work shows that stress on anhedonia and behavioral despair, synaptic plasticity of stress activates the transcription factor CREB and elevates target excitatory inputs to D1 and D2 MSNs, as well as changes in gene expression within the nucleus accumbens (NAc), and that intrinsic excitability. Furthermore, we determined whether synap- non-selective elevations in NAc CREB function produce tic and intrinsic excitability changes in D1 MSNs were sufficient depressive-like effects whereas disruptions in CREB function and necessary to drive stress-induced depressive behavior and produce antidepressant- and anxiolytic-like effects. Elevated NAc established that both synaptic and intrinsic changes cooperate to CREB function is associated with increased expression of promote this maladaptive behavior. dynorphin, an endogenous agonist at kappa-opioid receptors Results: In both male and female mice, footshock stress induces (KORs) that is co-expressed with GABA in dopamine D1 receptor- anhedonia and behavioral despair as assessed by the sucrose expressing medium spiny neurons (MSNs). Dynorphin, in turn, preference (n = 8 per group; t-test; t = 2.516(14); p = 0.0247) and produces feedback inhibition via KORs expressed on the cell forced swim tests (n = 7-8 per group; t-test; t = 3.488(13); p = bodies and terminals of ventral tegmental area (VTA) dopamine 0.004;), respectively. Ventral hippocampus (VH) inputs were neurons. Implicating dynorphin in the effects of CSDS on sleep, potentiated onto NAcc D1 MSNs (n = 9-13 per group; t-test; t administration of the KOR antagonist JDTic (10 mg/kg, IP) (20) = 3.47, p = 0.0024), but not D2 MSNs. Depotentiating VH mitigated CSDS-induced alterations in PS. Several lines of inputs to the NAcc rescued both stress-induced anhedonia (n = 9- evidence suggest that susceptibility to CSDS is accompanied by 13 per group; t-test; t(20) = 2.154, p = 0.0436) and behavioral reduced activity of D1-MSNs in the NAc; however, the ways in despair (n = 9-13 per group; t-test; t(20) = 3.47, p = 0.0024), which this neural population contributes to the persistent effects demonstrating that potentiation of VH inputs to D1 MSNs is of stress on sleep have not been thoroughly explored. Here we necessary for these effects. Intrinsic excitability was robustly examined how selective manipulation of D1-MSNs affects sleep enhanced in D1 MSNs from stressed mice (n = 22-32 per group; architecture, and the degree to which it can recapitulate effects of Two-way ANOVA; F(20, 730) = 6.39, p < 0.0001), while a modest CSDS on sleep-related endpoints. hypoexcitability was observed in D2 MSNs (n = 12-20 per group; Methods: We used a wireless EEG system that enables 1234567890();,: Two-way ANOVA; F(20, 470) = 2.03, p = 0.0056). Increased excit- continuous data collection in freely-moving male mice over a ability of D1 MSNs was mediated by a decrease in inwardly- period of weeks. To examine mechanisms of stress-induced sleep rectifying potassium currents mediated by KIR channels (n = 7-13 changes, we used viral vectors to express excitatory (hM3Dq) or per group; t-test; t(17) = 2.18, p = 0.043), which normally limit inhibitory (hM4Di) DREADDs (or mCherry control) in the NAc of excitability of MSNs. Overexpression of KIR channels selectively in mice expressing cre-recombinase in D1-MSNs (GENSAT FK-150). D1 MSNs rescued both stress-induced anhedonia (n = 6 per Mimicking the design of our previous CSDS study, after a 5-day group; t-test; t(10) = 6.542, p < 0.0001) and behavioral despair baseline, all mice received clozapine (0.3 mg/kg/day) in their (Two-way ANOVA; Treatment x Time Interaction; F(5, 70) = 2.701, drinking water for 10 days, followed by a 5-day washout. p = 0.0273). Furthermore, expression of dominant negative KIR Results: Chronic inhibition of D1-MSNs (via hM4Di) produced channels, which interfere with endogenous KIR function, was CSDS-like increases in PS time (F(2,24) = 12.87, p = 0.0002) with- sufficient to promote anhedonia and behavioral despair (n = 9 per out affecting slow wave sleep (SWS) or wakefulness (W) times. In group; t-test; t(16) = 2.707, p < 0.0001) in naïve animals. Lastly, we contrast, chronic activation of D1-MSNs (via hM3Dq) produced utilized novel disconnection procedures to demonstrate that decreases in PS time (F(2,20) = 4.662, p = 0.02), also without stress-induced depressive behaviors require both potentiation of affecting SWS or W times. These effects persisted following a 5- VH inputs to D1 MSNs and increased D1 MSN excitability. day DREADD ligand washout, suggesting that even transient Conclusions: Here we demonstrate that stress promotes activation or inhibition of this neuronal population can produce anhedonia and behavioral despair via cooperative increases in long-lasting effects on sleep.
Load more

Recommended publications
  • JUSTICE NEWS Opioid Manufacturer Insys Therapeutics Agrees to Enter
    JUSTICE NEWS Department of Justice Office of Public Affairs FOR IMMEDIATE RELEASE Wednesday, June 5, 2019 Opioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global Resolution of Criminal and Civil Investigations Company Admits Illegal Conduct Regarding Promotion of Subsys, a Powerful Opioid Painkiller Opioid manufacturer Insys Therapeutics agreed to a global resolution to settle the government’s separate criminal and civil investigations, the Department of Justice announced today. As part of the criminal resolution, Insys will enter into a deferred prosecution agreement with the government, Insys’s operating subsidiary will plead guilty to five counts of mail fraud, and the company will pay a $2 million fine and $28 million in forfeiture. As part of the civil resolution, Insys agreed to pay $195 million to settle allegations that it violated the False Claims Act. Both the criminal and civil investigations stemmed from Insys’s payment of kickbacks and other unlawful marketing practices in connection with the marketing of Subsys. Insys’s drug Subsys is a sublingual fentanyl spray, a powerful, but highly addictive, opioid painkiller. In 2012, Subsys was approved by the Food and Drug Administration for the treatment of persistent breakthrough pain in adult cancer patients who are already receiving, and tolerant to, around-the-clock opioid therapy. Today, the U.S. Attorney’s Office for the District of Massachusetts filed an Information charging Insys and its operating subsidiary with five counts of mail fraud. According to the charging document, from August 2012 to June 2015, Insys began using “speaker programs” purportedly to increase brand awareness of Subsys through peer-to-peer educational lunches and dinners.
    [Show full text]
  • The Bridge Between Science and the Future It Creates
    Cell Stem Cell Resource Review Communicating Hope: the Bridge between Science and the Future It Creates The Stem Cell Hope: How Stem Cell Medicine Can Change Our Lives Alice Park New York, Hudson Street Press (2011) 336 pp., ISBN: 978-1-59463-078-1 Stem cells and hope. For those who place their futures in the perpetuation of biomedical research, these two constructs— stem cells and hope—have become nearly synonymous. For the scientific community, the potential for their work to be the basis of hope seems all too obvious. Science has long been the very vehicle by which society tackles its most pressing and perplexing challenges. It was Vannevar Bush, the first US presi- dential science advisor and the intellectual powerhouse behind the National Science Foundation, who championed the role that science would need to play in addressing broad social, the opponents’ court. Park notes that the Bush advisor Jay Lef- economic, and technological problems. However, it was also kowitz himself stated, ‘‘A lot of the conservative groups saw Vannevar Bush who stated, ‘‘A belief may be larger than this .a little bit as a surrogate for abortion.’’ Language that a fact,’’ and for stem cell research, this perceptive observation has framed the debate, such as ‘‘cloning,’’ ‘‘destruction,’’ made over 50 years ago has come to define the field. ‘‘fetus,’’ ‘‘abortion,’’ and ‘‘slippery slope,’’ is the very language Alice Park works to dispel some of the ‘‘belief-as-fact’’ pattern introduced and perpetuated by those who have no greater that has driven the social side of stem cell research in her book, interest in the field than to see its demise.
    [Show full text]
  • SCRIPPS DISCOVERS FALL 2010 Selective Inhibition of BMK1 Suppresses Tumor Growth
    SC RIPPS DISC OVERS Accelerating Discoveries, Saving Lives A Newsletter for Philanthropists Published Quarterly by The Scripps Research Institute WINTER 2010 | VOL 7 | NO 1 California-Florida RESEARCH UPDATE Scripps Research Scientists Develop Molecular Test Providing a New Pathway for Identifying Obesity and Diabetes Drugs cientists at The Scripps Research Institute The Worm Institute for Research and Medicine have designed a new molecular test that at Scripps Research. Swill allow researchers to look for potential Janda and Amanda Garner, Ph.D., a research drugs targeting a human metabolic enzyme believed associate in his laboratory, described the new to stimulate the appetite and play a role in diabetes. approach—which may also prove useful for The new test, which the scientists call a simple investigating other enzymes involved in a assay, will allow researchers to look through variety of diseases—in an advance, online Early hundreds of thousands of compounds for those that Edition of the journal Angewandte Chemie on have potential to block the action of an enzyme September 15, 2010. known as ghrelin O-acyltransferase (GOAT). If Even though GOAT was only discovered drugs can be found that safely suppress the action recently, in 2008, scientists had speculated for of GOAT, they may help people who have clinical years that it had to exist. After all, its target (ghrelin, problems with appetite, obesity, and diabetes. or the “G” in the acronym GOAT) had been Professor Kim Janda “There hasn’t been a simple screen until now,” known for more than a decade. says Kim D. Janda, Ph.D., a professor in the Ghrelin, a small peptide hormone that is Departments of Chemistry and Immunology mainly produced in the stomach, signals hunger, and Microbial Science, member of The Skaggs typically before meals.
    [Show full text]
  • Scientists Turn Skin Cells Into Motor Neurons in ALS Patients
    Scientists Turn Skin Cells Into Motor Neurons in ALS Patients By Amanda Gardner HealthDay Reporter Thursday, July 31, 2008; 12:00 AM THURSDAY, July 31 (HealthDay News) -- Scientists have turned skin cells from patients with Lou Gehrig's disease into motor neurons that are genetically identical to the patients' own neurons. An unlimited number of these neurons can now be created and studied in the laboratory, a capability which should result in a better understanding of the disease and, one day, lead to new treatments or even the production of healthy cells that can replace the diseased ones. "The hope of some scientists is that they might be able to harness stem cells and program them to generate pluripotent stem cell lines [capable of differentiating into many different types of cells] which have the genes of patients," said Kevin Eggan, co-author of a paper appearing July 31 in the online version ofScience. "This would open up the possibility of producing a large supply of immune-matched cells to that patient that could be used in transplantation methodologies." "The other hope, and one that's much closer upon us . is if you could produce the cell types that become sick in that person, you might be able to use them in the laboratory to come to understand basic aspects of the disease and take the study of disease out of patients, where it's very difficult, and put it into the Petri dish," added Eggan, who is a principal faculty member at the Harvard Stem Cell Institute and spoke about the research at a teleconference Wednesday.
    [Show full text]
  • Reopening Avenues for Attacking Amyotrophic Lateral Sclerosis 15 July 2016, by Hannah L
    Reopening avenues for attacking amyotrophic lateral sclerosis 15 July 2016, by Hannah L. Robbins plays an important role in not only the nervous system, but also the blood and immune systems. "The point of our paper was to determine the function of this gene and what it normally helps to do in the body," said lead author Kevin Eggan, a professor in Harvard's Department of Stem Cell and Regenerative Biology (HSCRB) and an HSCI principal faculty member who has been studying ALS for more than a decade. According to Eggan, one way to better understand the gene is to catalog what is missing or goes awry when it is "knocked out," or inactivated. The scientists found that mice without a functional copy of the gene C9ORF72 had abnormally large spleens, livers, and lymph nodes, and got sick and In the murine spleen, lymphoid tissue (purple) is died. Mice with one working copy experienced responsible for launching an immune response to blood- similar but less severe changes. born antigens, while red pulp (pink) filters the blood. Mutations in the C9ORF72 gene, the most common mutation found in ALS patients, can inflame lymphoid "I realized immediately that the mouse knockout tissue and contribute to immune system dysfunction. had immune dysfunction," said Leonard Zon, a Credit: Dan Mordes, Eggan lab, Harvard Stem Cell professor in HSCRB, after seeing the preliminary Institute data at an informal presentation. The research team predicted that the gene mutation would affect neurons, but the finding that it Harvard Stem Cell Institute (HSCI) researchers at also inflamed other cells, namely those involved in Harvard University and the Broad Institute of autoimmunity, was "unexpected." With input from Harvard and MIT have found evidence that bone Zon and immunologist Luigi Notarangelo of Boston marrow transplantation may one day be beneficial Children's Hospital, the team decided to change to a subset of patients suffering from amyotrophic direction and further explore the gene's impact on lateral sclerosis (ALS), a fatal neurodegenerative the immune system.
    [Show full text]
  • Plenary and Platform Abstracts
    American Society of Human Genetics 68th Annual Meeting PLENARY AND PLATFORM ABSTRACTS Abstract #'s Tuesday, October 16, 5:30-6:50 pm: 4. Featured Plenary Abstract Session I Hall C #1-#4 Wednesday, October 17, 9:00-10:00 am, Concurrent Platform Session A: 6. Variant Insights from Large Population Datasets Ballroom 20A #5-#8 7. GWAS in Combined Cancer Phenotypes Ballroom 20BC #9-#12 8. Genome-wide Epigenomics and Non-coding Variants Ballroom 20D #13-#16 9. Clonal Mosaicism in Cancer, Alzheimer's Disease, and Healthy Room 6A #17-#20 Tissue 10. Genetics of Behavioral Traits and Diseases Room 6B #21-#24 11. New Frontiers in Computational Genomics Room 6C #25-#28 12. Bone and Muscle: Identifying Causal Genes Room 6D #29-#32 13. Precision Medicine Initiatives: Outcomes and Lessons Learned Room 6E #33-#36 14. Environmental Exposures in Human Traits Room 6F #37-#40 Wednesday, October 17, 4:15-5:45 pm, Concurrent Platform Session B: 24. Variant Interpretation Practices and Resources Ballroom 20A #41-#46 25. Integrated Variant Analysis in Cancer Genomics Ballroom 20BC #47-#52 26. Gene Discovery and Functional Models of Neurological Disorders Ballroom 20D #53-#58 27. Whole Exome and Whole Genome Associations Room 6A #59-#64 28. Sequencing-based Diagnostics for Newborns and Infants Room 6B #65-#70 29. Omics Studies in Alzheimer's Disease Room 6C #71-#76 30. Cardiac, Valvular, and Vascular Disorders Room 6D #77-#82 31. Natural Selection and Human Phenotypes Room 6E #83-#88 32. Genetics of Cardiometabolic Traits Room 6F #89-#94 Wednesday, October 17, 6:00-7:00 pm, Concurrent Platform Session C: 33.
    [Show full text]
  • Antiemetic/Antivertigo Agents – Dronabinol
    !ntiemetic/!ntivertigo !gents – dronabinol WA.PHAR.35 Antiemetic Antivertigo Agents Dronabinol Medical necessity Drug Medical Necessity Dronabinol (MARINOL®) Dronabinol may be considered medically necessary when: Dronabinol (SYNDROS®) Used for the treatment of ONE of the following 1. Anorexia associated with weight loss in adults with AIDS 2. Nausea and vomiting associated with chemotherapy in adults Clinical policy: Drug Clinical Criteria (Initial Approval) Dronabinol (MARINOL®) 1. Anorexia associated with weight loss in adults with AIDS Dronabinol (SYNDROS®) a. Defined by ONE of the following: i. Involuntary weight loss in adults of greater than 10% of pre-illness baseline body weight ii. BMI less than 20kg/m² in the absence of concurrent illness or medical condition other than AIDS that may cause weight loss b. History of failure, contraindication or intolerance to conventional therapies (e.g. megestrol (Megace®)) c. Dose limit: i. Marinol: 20mg per day ii. Syndros: 8.4mg twice daily 2. Prescribed by or in consultation with an HIV specialist Approve for 6 months Criteria (Reauthorization) 1. Continued diagnosis of AIDS wasting with continued wasting based on reduction of BMI 2. Documentation of positive clinical benefit Approve for 6 months Clinical Criteria (Initial Approval) 1. Nausea and vomiting associated with chemotherapy in adults a. Current diagnosis or cancer or history of cancer diagnosis in last year Policy: Dronabinol Last Updated 04/18/2018 1 b. Currently receiving chemotherapy or history of chemotherapy in the last year c. History of failure, contraindication or intolerance to conventional therapy (e.g. dexamethasone, ondansetron, aprepitant) 2. Dose limit: a. Marinol: 15mg/m² per dose for 4 to 6 doses per day b.
    [Show full text]
  • (ENU) Mutagenized Mouse Model for Autosomal Dominant Non-Syndromic Kyphoscoliosis Due to Vertebral Fusion
    This is a repository copy of An N -ethyl- N -nitrosourea (ENU) mutagenized mouse model for autosomal dominant non-syndromic kyphoscoliosis due to vertebral fusion. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/133327/ Version: Published Version Article: Esapa, C.T., Piret, S.E., Nesbit, M.A. et al. (13 more authors) (2018) An N -ethyl- N -nitrosourea (ENU) mutagenized mouse model for autosomal dominant non-syndromic kyphoscoliosis due to vertebral fusion. JBMR Plus, 2 (3). pp. 154-163. ISSN 2473-4039 https://doi.org/10.1002/jbm4.10033 Reuse This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ ORIGINAL ARTICLE An N-Ethyl-N-Nitrosourea (ENU) Mutagenized Mouse Model for Autosomal Dominant Nonsyndromic Kyphoscoliosis Due to Vertebral Fusion Christopher T Esapa,1,2Ã Sian E Piret,1Ã M Andrew Nesbit,1,3 Gethin P Thomas,4,5 Leslie A Coulton,6 Orla M Gallagher,6 Michelle M Simon,2 Saumya Kumar,2,7 Ann-Marie Mallon,2 Ilaria Bellantuono,6 Matthew A Brown,4 Peter
    [Show full text]
  • Unique Unique
    UNIQUE UNIQUE (ju^'ni^k) A. adj. 1. Of which there is only one; one and no other; single, sole, solitary. 2. a. That is or forms the only one of its kind; having no like or equal; standing alone in comparison with others, freq. by reason of superior excellence; unequalled, unparalleled, unrivalled. Oxford English Dictionary HSCI is a unique scientific enterprise THE HARVARD STEM CELL INSTITUTE is a unique scientific enterprise; nowhere else in the world are as many leading scientists gathered together to specifically focus on what today is one of the most important basic question in the life sciences: What is the property that allows stem cells not only to differentiate into any cell type in the body, but also makes it possible for them to reprogram other cells? And perhaps as significant, the Harvard Stem Cell Institute is a unique scientific enterprise because it is dedicated to bringing the answers to these questions to patients’ bedsides in the form of new treatments for conditions such as Parkinson’s disease, heart disease, cancer, blindness, and even dementias. scientific enterprise 4 } For a relatively brief interval ... researchers are Researchers believe that in as little as a decade it research solely on an individual lab basis, HSCI has hand, HSCI has established two major disease In 2005 HSCI provided its first dozen seed grants, intoxicated with a mix of the newly discovered may be possible to use embryonic stem cells to established collaborative platforms with other programs, the Cancer Stem Cell Program and The totaling $1.8 million, to launch innovative work by and the imaginable unknown.
    [Show full text]
  • Medical Marijuana for People Living with HIV
    Medical Marijuana for People Living with HIV Jasjit Gill, B.S.Pharm., Pharm.D., R.Ph. Director of HIV Pharmacy Services – UC Denver School of Medicine Pharmacy Manager, Clinical Pharmacy Specialist Co-Chair, Vaccine Committee, Pharmacy & Therapeutics University of Colorado Hospital Infectious Disease Group Practice – Pharmacy Aurora, Colorado 1 Learning Objectives ♦ Review the laws and history of cannabinoids ♦ Describe the complexity of pharmacokinetic parameters of marijuana and how they may affect patient care ♦ Identify possible drug-drug interactions, side effects or adverse drug reactions with medical marijuana in healthcare 2 Marijuana Law ♦ Medical + recreational use is approved in 14 states ■ 34 states including District of Columbia, Guam, Puerto Rico and US Virgin Islands have medical marijuana laws ■ 12 states allow low THC, high CBD products for medical reasons in limited situations ■ Mariana Islands are the only territory to have recreational use only, no medical use http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx laws 3 A Brief History of Medicinal Marijuana ♦ Controlled Substance Act ♦ Scheduling ■ FDA ■ DHHS – Federal registry ■ NIDA ■ DEA ♦ Colorado ■ November 2000 Amendment 20 ■ 2010 the Colorado Legislature passed HB-1284 ■ November 2012 Amendment 64 4 Medical Marijuana in Healthcare ♦ China 2737 B.C ♦ No official US standards for herbals ♦ No German Commission E monograph ♦ US Pharmacopeia 1850 – 1942 ♦ 1937 Marijuana Tax Act ♦ Merck Index until 1950 ♦ Dronabinol Orphan Drug status 1985 ♦ No federally recognized use of marijuana 5 Dosage Forms ♦ Flowered Plant Dried (oral or inhaled) ♦ Hashish – Pure Resin ♦ Oil Hashish (5-10 times more potent) ♦ Capsule Marinol® , Nabilone® ♦ Buccal Spray Sativex® ♦ Solution Epidiolex® (purified CBD) ♦ Solution Syndros® (Dronabinol) 6 New Drugs approved by FDA ♦ Epidiolex (purified CBD) - (Schedule V) approved for add-on therapy for treatment of seizures related to Lennox-Gastaut and Dravet Syndrome.
    [Show full text]
  • 2017 Denman Undergraduate Research Forum Accepted Student Abstracts Laboratory/Cellular Health Sciences
    2017 Denman Undergraduate Research Forum Accepted Student Abstracts Laboratory/Cellular Health Sciences Category: Laboratory/Cellular Health Sciences Title: The nuclear pore complex protein NupA is required for normal localization of the mRNA export factor Gle1 in Aspergillus nidulans Student Presenter: Leymaan Abdurehman Faculty Advisor: Osmani, Stephen Abstract: Mitosis is a fundamental process for the development of multicellular organisms. While significant insights have been obtained into mitotic mechanisms, the disassembly and reassembly of Nuclear Pore Complexes (NPCs) is not well understood. NPCs carry out transport across the nuclear envelope. During mitosis in Aspergillus nidulans, NPCs are disassembled during mitotic entry. Some NPC proteins locate to mitotic structures and operate transport functions in interphase. NupA was identified as a novel NPC protein that co-purified with the conserved NPC protein Nup2 during interphase and mitosis. During mitosis, both proteins locate to mitotic chromatin with unknown functional significance. Deletion of NupA leads to activation of the Spindle Assembly Checkpoint (SAC) as well as late mitotic defects. NupA was found to be important for normal localization of NPC proteins Mad1 and Ndc1. We are interested in determining whether additional NPC proteins localization depends on NupA. As a candidate, we chose Gle1, an essential NPC protein involved in mRNA export. To delete NupA, a gene replacement construct was generated by fusion PCR and transformed into A. nidulans. Since NupA is an essential gene, we analyzed the phenotype of its deletion using the heterokaryon rescue technique. NupA deletion was confirmed through diagnostic PCR with primers flanking the deletion construct. Live cell confocal microscopy indicated that the localization of Gle1-GFP was affected in the absence of NupA.
    [Show full text]
  • Scientists Report a Breakthrough in Stem Cell Production Created Cells That Match Those in ALS Patient
    THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING Scientists report a breakthrough in stem cell production Created cells that match those in ALS patient By Carolyn Y. Johnson, Globe Staff | August 1, 2008 Reaching a milestone in stem cell research, scientists at Harvard and Columbia universities reported yesterday that they created the first stem cell lines from a sick person, then coaxed these cells to become nerve cells genetically matched to those that had gone bad in a patient's spinal cord. In a paper published online in the journal Science, the team claimed success at what researchers have long been racing to do: create in the laboratory a plentiful supply of cells that have the same genetic makeup as a patient with a particular disease. The work was done with patients suffering from ALS, or Lou Gehrig's disease, but the researchers said the same technique can be used to study many other genetic diseases. By comparing diseased cells to normal cells in a Petri dish, scientists hope to better understand what causes disease and test new drugs. A series of dramatic discoveries over the past two years has pushed stem cell science forward, so this advance was expected. Still, the scientists were thrilled to have accomplished a task that was a fundamental reason for doing stem cell research in the first place. "Since the cloning of Dolly the sheep and the first derivation of a human embryonic stem cell line by Jamie Thomson some 10 years ago, it's been the hope of scientists . to generate stem cell lines that have the genes of a patient," said Kevin Eggan, coauthor of the paper and a principal faculty member of the Harvard Stem Cell Institute.
    [Show full text]